Bladder stone
Methodology & AI Transparency ⓘ
Bladder stone Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Bladder stone (N21.0; Prostate (BPH), Bladder & Urinary Tract) utilize hydration citrate protocols [Bladder stone N21.0] and objective Urinalysis & Post-Void in Bladder stone (N21.0: Residual (PVR)) targets (Negative leukocyte/nitrite; PVR < 50 mL (N21.0)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Mapped to Prostate (BPH), Bladder & Urinary Tract under ICD-10-CM N21.0 for Bladder stone clinical workups.
- 3 Typical cash cost range: Workup highlights for Bladder stone (N21.0): hydration citrate protocols [Bladder stone N21.0].
- 4 Top reported side effects / signs: Key Urology & Prostate biomarkers for Bladder stone (N21.0): Urinalysis & Post-Void in Bladder stone (N21.0: Residual (PVR)) & Total PSA & in Bladder stone (N21.0: Serum Creatinine/eGFR) (Age-specific PSA; eGFR > 75 mL/min (N21.0)).
Ask our AI Specialists anything about Bladder stone
What Is Bladder stone?
Physicians managing Bladder stone (N21.0; Prostate (BPH), Bladder & Urinary Tract) utilize hydration citrate protocols [Bladder stone N21.0] and objective Urinalysis & Post-Void in Bladder stone (N21.0: Residual (PVR)) targets (Negative leukocyte/nitrite; PVR < 50 mL (N21.0)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Bladder stone (N21.0, Urology & Prostate) reflects or detrusor overactivity [Bladder stone N21.0]. longitudinal control is benchmarked via Urinalysis & Post-Void in Bladder stone (N21.0: Residual (PVR)).
Common Symptoms & Clinical Signs
- • Presentation of Bladder stone (N21.0): burning dysuria, suprapubic in Bladder stone (N21.0: discomfort, or cloudy/hematuric)
- • Secondary Bladder stone clinical sign: sudden severe flank-to-groin in Bladder stone (N21.0: colicky pain caused)
- • Symptom flares in Bladder stone correlating with Urinalysis & Post-Void in Bladder stone (N21.0: Residual (PVR)) deviation outside Negative leukocyte/nitrite; PVR < 50 mL (N21.0)
- • Functional urology & prostate impact requiring hydration citrate protocols [Bladder stone N21.0] evaluation (N21.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Bladder stone Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N21.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Bladder stone (N21.0: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (N21.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total PSA & in Bladder stone (N21.0: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (N21.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Bladder stone (N21.0: Score) | 0 – 7 (mild symptoms) (N21.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Bladder stone
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Bempedoic Acid and Ezetimibe Nexlizet • RxCUI RXN-72426818-2250 | Adenosine Triphosphate-Citrate Lyase Inhibitor | 78% | $13.7964 | $ 185.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bladder stone)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder: What a 538-Participant Study Found In this post hoc responder analysis from the phase 3 COURAGE trial, participants receiving vibegron vs placebo achieved clinically relevant reductions in bothersome OAB symptoms, as well as improvements in IPSS and OAB-q scores. Urology • 2025-12-15 • Phase III Randomized Trial | N = 538 | 93/100 | PMID 40902908 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of onabotulinumtoxinA in patients with overactive bladder: OnabotulinumtoxinA was efficacious and well tolerated in women and in men with lower PSA levels. International urology and nephrology • 2021-11-15 • Phase III Randomized Trial | N = 186 | 88/100 | PMID 34292493 ↗ |
| Can This Approach Help? Inside the Latest Research on Treatment preferences affect the therapeutic alliance: implications for The congruence of patients' treatment preference and the treatment that they ultimately received influenced the development of the therapeutic alliance. Journal of consulting and clinical psychology • 2007-02-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 17295580 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of skin-adhesive low-level light therapy for overactive LLLT may be clinically useful and safe for the treatment of OAB. International urogynecology journal • 2022-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35389054 ↗ |
| New Insights on Efficacy of mirabegron, a β 3 -adrenoreceptor agonist, in Japanese women with: What a 204-Participant Study Found Mirabegron 50 mg significantly improved key overactive bladder symptoms versus placebo in women with urgency urinary incontinence, and it also improved most overactive bladder symptoms, including micturition frequency, in... International journal of urology : official journal of the Japanese Urological Association • 2022-01-15 • Phase III Randomized Trial | N = 204 | 88/100 | PMID 34605079 ↗ |
Bladder stone Patient Community & “People Like Me” Threads
Filter Bladder stone community threads and patient logs by age, biological sex, dosage, and treatment duration.